UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: February 13, 2019 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure Provides Update on Release of
Holdback Funds from Apicore Sale
WINNIPEG, Feb. 13, 2019 /CNW/ - Medicure
Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company,
today announced that it has received notice from the purchaser of Medicure's interests in Apicore of potential claims against funds
held back in respect of representations and warranties under the Apicore sale agreement. The notice does not contain sufficiently
detailed information to enable Medicure to assess the merits or size of the claims at this stage. Nevertheless, Medicure will proceed
diligently to investigate the potential claims and attempt to satisfactorily resolve them with a view to having the holdback funds
released as quickly as possible. In conjunction with the sale of Medicure's interests in Apicore, representation and warranty insurance
was obtained by the purchaser that could result in mitigation of the potential claims.
About Medicure
Medicure is a pharmaceutical company focused
on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the
marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin)
tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma
Inc. For more information on Medicure please visit www.medicure.com.
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
Forward Looking Information: Statements
contained in this press release that are not statements of historical fact, including, without limitation, statements containing
the words "believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking
information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information
and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking
statements, include, the Company's success in resolving the claims made against the holdback funds under the Apicore sale agreement,
the timing of the release of the holdback funds under the Apicore sale agreement, the potential of representation and warranty
insurance to respond to claims made by the Apicore purchaser, estimates, analysis and opinions of management of the Company made
in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors
which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known
and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual
results, events or developments to be materially different from any future results, events or developments expressed or implied
by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements.
Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital requirements,
risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products,
the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory
approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which
may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact
of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the
receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing
for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable
terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products
and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required
by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business
can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities
and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2017.
AGGRASTAT® (tirofiban hydrochloride)
is a registered trademark of Medicure International Inc.
View
original content:http://www.prnewswire.com/news-releases/medicure-provides-update-on-release-of-holdback-funds-from-apicore-sale-300795249.html
SOURCE Medicure Inc.
View original content: http://www.newswire.ca/en/releases/archive/February2019/13/c8190.html
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 17:00e 13-FEB-19
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Sep 2023 to Sep 2024